Sumit Kumar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sumit Kumar has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Anu Saini
Department of Chemistry Guru Nanak Dev University Amritsar India
1 shared publication- Aurora Martinez
Department of Biomedicine University of Bergen Bergen Norway
1 shared publication - Bengt Erik Haug
Department of Chemistry and Centre for Pharmacy, University of Bergen, Allégaten 41, 5007 Bergen, Norway
1 shared publication - Daniela Mauceri
Department of Neurobiology, Interdisciplinary Centre for Neurosciences (IZN), Heidelberg University, Heidelberg, Germany
1 shared publication Dorothea Schall
Institute of Human Genetics
1 shared publication- Jan Haavik
Department of Biomedicine, University of Bergen, Bergen, Norway
1 shared publication
Latest Publications
- 16 November 2026
- Published by Wiley in ChemMedChem
- Vol. 21 (22)
Design, Synthesis and Anti‐Proliferative Assessment of 4‐Aminoquinoline‐ and 4‐Aminoquinoline‐Benzoxaborole Conjugates
A series of 4‐aminoquinoline analogues and 4‐aminoquinoline‐benzoxaborole conjugates were synthesized and evaluated for their antiproliferative activities against two distinct breast cancer cell lines: MCF‐7 (estrogen receptor‐positive, ER+) and MDA‐MB‐231 (triple‐negative). Preliminary dose‐response assays revealed compound 5e , a 4‐aminoquinoline–benzoxaborole conjugate, as the most active compound against MCF‐7 cells. Structure–activity relationship (SAR) analysis indicated that the cytotoxic potency of the series increased with the length of the alkyl spacer connecting the pharmacophoric moieties. To assess selectivity, HEK‐293 cells were employed as a non‐cancerous control line, and most compounds exhibited minimal cytotoxicity, except compound 5d , which showed moderate effects. To gain preliminary structural insights, exploratory molecular docking studies were performed against the ligand‐binding domain of estrogen receptor alpha (ERα). This integrated experimental‐computational approach highlights the identification of promising preliminary hits. Overall, the findings show that 4‐aminoquinoline–benzoxaborole conjugates exhibit antiproliferative activity against breast cancer cells, with greater potency towards MCF‐7 cells.
- 16 November 2026
- Published by Wiley in ChemMedChem
- Vol. 21 (22)
Design, Synthesis and Anti‐Proliferative Assessment of 4‐Aminoquinoline‐ and 4‐Aminoquinoline‐Benzoxaborole Conjugates
A series of 4‐aminoquinoline analogues and 4‐aminoquinoline‐benzoxaborole conjugates were synthesized and evaluated for their antiproliferative activities against two distinct breast cancer cell lines: MCF‐7 (estrogen receptor‐positive, ER+) and MDA‐MB‐231 (triple‐negative). Preliminary dose‐response assays revealed compound 5e , a 4‐aminoquinoline–benzoxaborole conjugate, as the most active compound against MCF‐7 cells. Structure–activity relationship (SAR) analysis indicated that the cytotoxic potency of the series increased with the length of the alkyl spacer connecting the pharmacophoric moieties. To assess selectivity, HEK‐293 cells were employed as a non‐cancerous control line, and most compounds exhibited minimal cytotoxicity, except compound 5d , which showed moderate effects. To gain preliminary structural insights, exploratory molecular docking studies were performed against the ligand‐binding domain of estrogen receptor alpha (ERα). This integrated experimental‐computational approach highlights the identification of promising preliminary hits. Overall, the findings show that 4‐aminoquinoline–benzoxaborole conjugates exhibit antiproliferative activity against breast cancer cells, with greater potency towards MCF‐7 cells.
- Open Access
- 21 May 2026
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 17 (11) , 2203-2218
Discovery of Small-Molecule Inhibitors of the KCNQ1/Kv7.1 Potassium Channel with Virtual Screening and Functional Validation in Electrophysiological Assays and KCNQ1-Knockout Neural Stem Cells
Voltage-gated potassium channel KCNQ1 (Kv7.1) plays a critical role in electrical excitability in the heart, gut, and brain. Together with the auxiliary subunit KCNE1, KCNQ1 generates a slow delayed rectifier current (IKs) that is essential for cardiac repolarization. Mutations and dysregulation of this channel are found in channelopathies leading to sudden death, long-QT syndrome, atrial fibrillation, epilepsy, deafness, diabetes, and neuropsychiatric disorders. Although KCNQ1 and related potassium channels are promising therapeutic targets, there are few potent, selective, and therapeutically safe inhibitors and activators available for these proteins. A virtual screening of 36,374 compounds was conducted against KCNQ1, followed by in silico analyses that identified eight potential ligand candidates for experimental evaluation using human KCNQ1 coexpressed with KCNE1 in Xenopus laevis oocytes. Electrophysiological recordings showed that the benzodiazepine-based ligand Zinc13732787 was a potent inhibitor of the channel complex, without affecting KCNQ2/KCNQ3. Based on virtual screening and molecular docking, the 1-(3-chlorophenyl)-urea substituent on the benzodiazepine core is important for selective inhibition of KCNQ1/KCNE1, as further supported by structure-activity relationship and stereochemical exploration of Zinc13732787. Furthermore, low concentrations of Zinc13732787 reduced neurite outgrowth in human neuronal stem cells (NSCs), mirroring the phenotype observed in homozygous KCNQ1-knockout cells. Importantly, Zinc13732787 did not affect NSC proliferation, nor did it induce cytotoxicity. In homozygous KCNQ1-knockout NSCs, compound Zinc13732787 had no effect on neurite outgrowth, indicating high target specificity. These findings suggest that this compound is a valuable tool for investigating the physiological and pathological roles of KCNQ1 across various tissues. Additionally, it could be used as a precursor for novel antiarrhythmic agents as well as for epilepsy and neuropsychiatric conditions.
- 21 May 2026
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 17 (11) , 2203-2218
Open AccessDiscovery of Small-Molecule Inhibitors of the KCNQ1/Kv7.1 Potassium Channel with Virtual Screening and Functional Validation in Electrophysiological Assays and KCNQ1-Knockout Neural Stem Cells
Voltage-gated potassium channel KCNQ1 (Kv7.1) plays a critical role in electrical excitability in the heart, gut, and brain. Together with the auxiliary subunit KCNE1, KCNQ1 generates a slow delayed rectifier current (IKs) that is essential for cardiac repolarization. Mutations and dysregulation of this channel are found in channelopathies leading to sudden death, long-QT syndrome, atrial fibrillation, epilepsy, deafness, diabetes, and neuropsychiatric disorders. Although KCNQ1 and related potassium channels are promising therapeutic targets, there are few potent, selective, and therapeutically safe inhibitors and activators available for these proteins. A virtual screening of 36,374 compounds was conducted against KCNQ1, followed by in silico analyses that identified eight potential ligand candidates for experimental evaluation using human KCNQ1 coexpressed with KCNE1 in Xenopus laevis oocytes. Electrophysiological recordings showed that the benzodiazepine-based ligand Zinc13732787 was a potent inhibitor of the channel complex, without affecting KCNQ2/KCNQ3. Based on virtual screening and molecular docking, the 1-(3-chlorophenyl)-urea substituent on the benzodiazepine core is important for selective inhibition of KCNQ1/KCNE1, as further supported by structure-activity relationship and stereochemical exploration of Zinc13732787. Furthermore, low concentrations of Zinc13732787 reduced neurite outgrowth in human neuronal stem cells (NSCs), mirroring the phenotype observed in homozygous KCNQ1-knockout cells. Importantly, Zinc13732787 did not affect NSC proliferation, nor did it induce cytotoxicity. In homozygous KCNQ1-knockout NSCs, compound Zinc13732787 had no effect on neurite outgrowth, indicating high target specificity. These findings suggest that this compound is a valuable tool for investigating the physiological and pathological roles of KCNQ1 across various tissues. Additionally, it could be used as a precursor for novel antiarrhythmic agents as well as for epilepsy and neuropsychiatric conditions.
- Open Access
- 31 January 2024
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 10 (2) , 251-269
Unlocking Opportunities for Mycobacterium leprae and Mycobacterium ulcerans
In the recent decade, scientific communities have toiled to tackle the emerging burden of drug-resistant tuberculosis (DR-TB) and rapidly growing opportunistic nontuberculous mycobacteria (NTM). Among these, two neglected mycobacteria species of the Acinetobacter family, Mycobacterium leprae and Mycobacterium ulcerans, are the etiological agents of leprosy and Buruli ulcer infections, respectively, and fall under the broad umbrella of neglected tropical diseases (NTDs). Unfortunately, lackluster drug discovery efforts have been made against these pathogenic bacteria in the recent decade, resulting in the discovery of only a few countable hits and majorly repurposing anti-TB drug candidates such as telacebec (Q203), P218, and TB47 for current therapeutic interventions. Major ignorance in drug candidate identification might aggravate the dramatic consequences of rapidly spreading mycobacterial NTDs in the coming days. Therefore, this Review focuses on an up-to-date account of drug discovery efforts targeting selected druggable targets from both bacilli, including the accompanying challenges that have been identified and are responsible for the slow drug discovery. Furthermore, a succinct discussion of the all-new possibilities that could be alternative solutions to mitigate the neglected mycobacterial NTD burden and subsequently accelerate the drug discovery effort is also included. We anticipate that the state-of-the-art strategies discussed here may attract major attention from the scientific community to navigate and expand the roadmap for the discovery of next-generation therapeutics against these NTDs.
- 31 January 2024
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 10 (2) , 251-269
Open AccessUnlocking Opportunities for Mycobacterium leprae and Mycobacterium ulcerans
In the recent decade, scientific communities have toiled to tackle the emerging burden of drug-resistant tuberculosis (DR-TB) and rapidly growing opportunistic nontuberculous mycobacteria (NTM). Among these, two neglected mycobacteria species of the Acinetobacter family, Mycobacterium leprae and Mycobacterium ulcerans, are the etiological agents of leprosy and Buruli ulcer infections, respectively, and fall under the broad umbrella of neglected tropical diseases (NTDs). Unfortunately, lackluster drug discovery efforts have been made against these pathogenic bacteria in the recent decade, resulting in the discovery of only a few countable hits and majorly repurposing anti-TB drug candidates such as telacebec (Q203), P218, and TB47 for current therapeutic interventions. Major ignorance in drug candidate identification might aggravate the dramatic consequences of rapidly spreading mycobacterial NTDs in the coming days. Therefore, this Review focuses on an up-to-date account of drug discovery efforts targeting selected druggable targets from both bacilli, including the accompanying challenges that have been identified and are responsible for the slow drug discovery. Furthermore, a succinct discussion of the all-new possibilities that could be alternative solutions to mitigate the neglected mycobacterial NTD burden and subsequently accelerate the drug discovery effort is also included. We anticipate that the state-of-the-art strategies discussed here may attract major attention from the scientific community to navigate and expand the roadmap for the discovery of next-generation therapeutics against these NTDs.